In a phase II study, two novel HIV vaccine platforms were safe and immunogenic. Will they protect against HIV infection?
Finding an HIV vaccine has proven to be harder than anyone initially predicted. Up to now, only one of four efficacy trials has demonstrated (modest) protection against HIV infection (NEJM JW AIDS Clin Care Dec 2009 and N Engl J Med 2009; 361:2209). In a new, partially manufacturer-sponsored trial of safety and immunogenicity, prime-boost vaccine regimens using two uncommonly found human adenovirus vectors (Ad26 and Ad35) were tested in different combinations. The vaccine included an HIV clade A envelope gene. This vaccine has shown to be protective against HIV-1 in the nonhuman primate model as well as safe in phase I clinical trials.
Of 218 adults randomized in the U.S. and several African countries, 49% were women and 78% were black (67% …
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)